OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
January 02, 2021
The number of recommendations for European marketing authorization of human medicines saw significant increase in 2020 over the previous year.
December 23, 2020
The virtual manufacturer and distributor of specialty materials acquired the NY-based company, adding analytical and manufacturing expertise.
December 16, 2020
A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.
December 15, 2020
The companies are entering into a license and collaboration agreement for the development and commercialization of Relay’s investigational cancer treatment, RLY-1971, a potent inhibitor of SHP2, a molecule that plays a role in cancer cell survival.
December 10, 2020
With the acquisition, Evonik will expand its life science division and its portfolio of functional excipients and biomaterials.
Evonik offers lipid nanoparticles for gene-based drug development and manufacturing.
December 03, 2020
Under the terms of the partnership, Colorcon will work to accelerate i2O’s research and development efforts.
Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.
Study results indicate that fatty alcohols may plausibly enhance the skin permeation of clotrimazole.
December 02, 2020
The investment will expand and upgrade manufacturing capacity and technology for pre-fillable syringes and will also includes a new manufacturing facility in Europe.